-
My Account
In App
My Account
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 1 | 879.60 | 887.15 | 44 |
| 44 | 875.15 | 899.50 | 5 |
| 10 | 875.00 | 922.25 | 150 |
| 20 | 874.00 | 925.80 | 1 |
| 1 | 873.95 | 935.00 | 50 |
| 0 | Total | Total | 0 |
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 1 | 879.60 | 887.15 | 44 |
| 44 | 875.15 | 899.50 | 5 |
| 10 | 875.00 | 922.25 | 150 |
| 20 | 874.00 | 925.80 | 1 |
| 1 | 873.95 | 935.00 | 50 |
| 0 | Total | Total | 0 |
| Open | 892.90 |
| Previous Close | 872.05 |
| Volume | 184,287.00 |
| Value (Lacs) | 1,628.64 |
| VWAP | 884.29 |
| Beta | |
| Mkt Cap (Rs. Cr.) | 10,842 |
| High | 893.00 |
| Low | 873.00 |
| UC Limit | 1,046.45 |
| LC Limit | 697.65 |
| 52 Week High | 1,251.00 |
| 52 Week Low | 850.00 |
| Face Value | 2.00 |
| All Time High | 1,335.10 |
| All Time Low | 370.00 |
| 20D Avg Volume | 275,709 |
| 20D Avg Delivery(%) | 32.17 |
| Book Value Per Share | -- |
| Dividend Yield | 0.57 |
| TTM EPS See historical trend | 0.00 (+25.08% YoY) |
| TTM PE See historical trend | -- (Average PE) |
| P/B See historical trend | 0.00 (Average P/B) |
| Sector PE | 40.19 |
*Delayed by 20 seconds.
Stock Score
Get detailed analysis with Moneycontrol Stock Insights.
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| Days | |
|---|---|
| 5 | - - |
| 10 | - - |
| 20 | - - |
| 50 | - - |
| 100 | - - |
| 200 | - - |
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| Days |
|---|
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| Days |
|---|
| 1 Week | --% | |
| 1 Month | --% | |
| 3 Months | --% | |
| YTD | --% | |
| 1 Year | --% | |
| 3 Years | --% |
3 out of 5 years Glenmark Life Sciences has given negative returns in December.
| Month | Max. Positive Change(%) | Avg. Positive Change(%) | Max. Negative Change(%) | Avg. Negative Change(%) | Average Change(%) |
|---|---|---|---|---|---|
| December | 4.28% (2023) | 3.72% | -9.28% (2024) | -4.27% | -1.07% |
Alivus Life Sciences to Meet Investors/Analysts on Sept 2, 2025 Aug 26 2025 11:53 AM
Alivus Life Standalone June 2025 Net Sales at Rs 601.85 crore, up 2.25% Y-o-Y Aug 05 2025 12:06 PM
Stocks to Watch Today: ABB India, Dilip Buildcon, ITC, Railtel Corp, Hero MotoCorp, Delhivery, MCX, Muthoot Capital, Harsha Engineers in focus on 4 August Aug 04 2025 02:59 AM
Alivus Life Standalone March 2025 Net Sales at Rs 649.55 crore, up 21.05% Y-o-Y May 16 2025 10:35 AM
ICICI Prudential Mutual Fund bought 9.70 lakh shares 0.70 percent at Rs 870 each. View more
Posted by : kamal20
Posted by : The Fixed Income
Repost this message
Lock in a Steady 9.15% from a Trusted NBFC Bond 9.15% VIVRITI CAPITAL LIMITED 2027 ✔️ Coupon: 9.15% ✔️ Rating: CARE A+ Stable ✔️ Tenor: 1y 10m (Maturity: 04 Nov 2027) Senior Secured | High-Return | NBFC Bond | Listed Add a reliable, secured NBFC bond to your portfolio and benefit from consistent yields with medium-term tenure. ???? Explore on The Fixed Income: https://www.thefixedincome.com/product/dVJDc1lRPT0=/1060-navi-finserv-limited-2027?utm_source=Moneycontrol&utm_medium=Forum&utm_campaign=Product_list
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
| Qty 969912 | Price 870 | % Traded 0.79 |
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
| Date | Agenda |
|---|
| Ex-Date | Type | Dividend (Rs) |
|---|
| Announcement Date | Ex-Bonus | Ratio |
|---|
| Ex-Split | Old FV | New FV |
|---|
| Ex-Right | Ratio | Premium |
|---|
| Date | Agenda |
|---|
| Company Name | Price | % Chg | MCap(Cr) | TTM PE | P/B | ROE(%) | 1 Yr Perform(%) | Net Profit(Rs.) | Net Sales(Rs.) | Debt to Equity |
|---|---|---|---|---|---|---|---|---|---|---|
| Alivus Life | 883.75 | 1.34 | 10,841.96 | 20.44 | 3.85 | 17.23 | -17.80 | 485 | 2,386 | 0.00 |
| Sun Pharma | 1,805.30 | -0.71 | 433,151.94 | 41.45 | 6.00 | 15.13 | -0.45 | 10,980 | 52,578 | 0.03 |
| Divis Labs | 6,473.50 | 0.07 | 171,851.09 | 69.15 | 11.48 | 14.63 | 6.19 | 2,191 | 9,360 | 0.00 |
| Torrent Pharma | 3,785.90 | -0.26 | 128,132.06 | 59.88 | 17.07 | 25.17 | 12.63 | 1,911 | 11,516 | 0.40 |
| Cipla | 1,520.80 | -0.01 | 122,845.85 | 22.58 | 3.94 | 16.90 | 1.51 | 5,291 | 27,547 | 0.00 |
Sharpest Opinions & Actionable Insights 
Exclusive Webinars 
Research & Expert Technical Analysis 
